Posted by: Clear Vision Cataract & LASIK Center

If you or someone you know is approaching cataract surgery, the conversation used to go one of two ways:

  • You either chose a single vision lens and planned on wearing glasses afterward
  • You chose an advanced multifocal lens and hoped the trade-off, some halos, some glare, reduced contrast at night, was worth the reduced glasses dependence.

In exciting news, that trade-off just got a lot smaller.

Johnson & Johnson received FDA approval for the TECNIS PureSee IOL in March 2026, which is a next-generation extended depth of focus lens that delivers something the previous generation of advanced technology lenses couldn’t quite manage: a wide range of vision without the visual disturbances that some patients just didn’t love.

Clear Vision Center is among the first practices in Michigan to offer it. And early patient response has been promising.

What Makes PureSee Different From Other Advanced Technology Lenses

Most advanced technology lenses on the market today work by dividing light. The lens has tiny rings built into it that split incoming light so your eye can focus at multiple distances at once. It’s clever engineering, but divided light is divided light. Some of it goes to distance, some to near, and what you’re left with at any given moment is a fraction of what came in. That’s the physics behind why some patients end up with halos around headlights or notice that their night vision isn’t quite as crisp as they expected.

The TECNIS PureSee takes a different approach entirely. It’s a purely refractive extended depth of focus lens, meaning it uses a continuous gradient in the lens surface to smoothly extend the range of focus rather than dividing light. The result is a wider visual range that still maintains nearly the same contrast sensitivity of a standard monofocal lens.

It’s the first FDA-approved EDOF lens that carries no warning for loss of contrast sensitivity. That’s a meaningful distinction, and it’s one reason surgeons have taken notice.




What the Clinical Data Actually Shows

The numbers behind PureSee are among the strongest we’ve seen for an advanced technology lens launch.

In the FDA clinical trial, 97% of patients reported no bothersome visual disturbances. In real-world data presented at the American Society of Cataract and Refractive Surgery annual meeting in April 2026, drawing on 293 patients across 19 sites in Europe and Asia-Pacific, average uncorrected distance vision came in at 20/19. Which is better than the 20/20 standard most people think of as perfect.

On the question of halos and glare, the thing people worry most about with premium lenses, 93% of patients reported little or no bothersome halos, 91% reported little or no bothersome glare, and 92% reported little or no bothersome starbursts.

Spectacle independence was reported in 96% of patients for distance vision and 95% for intermediate vision. For near vision, reading fine print, phone screens, and menus, 61% reported independence from glasses. For patients who want a lens that handles most of daily life without reaching for readers, that’s a strong result.

Who Is a Good Candidate

PureSee is an advanced technology EDOF lens, which means it’s an upgrade from a standard monofocal which is not typically something covered by routine insurance. It’s worth the conversation if you:

  • Are scheduled for cataract surgery and want to reduce or eliminate your dependence on glasses afterward
  • Have previously been hesitant about advanced technology lenses because of concerns about halos, glare, or reduced night vision quality
  • Have an active lifestyle and want strong distance and intermediate vision: driving, computer work, reading in the car, with less reliance on glasses for most tasks
  • Are farsighted or dealing with presbyopia on top of your cataract diagnosis

It’s also worth knowing that PureSee is available in a toric version, which means patients with astigmatism can address that at the same time.

Like any advanced technology lens, candidacy is determined by the specifics of your eyes: overall health of the eyes, the degree of astigmatism, and your visual goals. What works exceptionally well for one patient isn’t always the right fit for another. That determination should always happen in a thorough pre-surgical consultation.

Why It Matters That Clear Vision Center Has PureSee Now

When you’re choosing a lens that stays in your eye for the rest of your life, the word “new” can feel more unsettling than exciting. Worth knowing then: PureSee is built on a lens platform, TECNIS, made by Johnson & Johnson, that has been used in cataract surgery for 25 years, with millions of patients worldwide. The foundation is about as established as it gets. What changed is the optics.

Practices that are among the first to adopt a lens like this aren’t just early adopters. They’re the ones who pursued the training, evaluated the clinical data, and made a deliberate decision that this technology was ready and right for their patients. Which is what happened here at Clear Vision Center.

What Patients Are Saying

We’ll let the early results from our own patients speak when the time is right, but what we can say is that the early feedback has matched what the clinical data predicted. Patients who came in expecting to manage trade-offs are leaving without them and that’s something we are all thrilled about.

Schedule a Consultation

If you’re approaching cataract surgery, or if you’ve been told cataracts are developing and you’re wondering what your options look like, we’d encourage you to come in before you make any decisions. The lens you choose at the time of surgery is the lens you live with and it’s worth taking the time to choose the right one.

Clear Vision Center serves Rochester Hills and Bloomfield Hills. Call us at (248) 215-0326 or schedule a consultation at clearvisioncenter.com.